Understand the source comparison
VIP Fibromyalgia Research Mechanism: Key Clinical Findings Comparison
Fibromyalgia patients (n=84) 25 mcg intranasal BID, 12 weeks FIQ score reduction −18.3 points vs −6.1 placebo VPAC2-mediated glial inhibition Statistically significant but requires larger cohort validation Chronic pain rodent model 100 mcg/kg SC daily, 4 weeks
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Fibromyalgia patients (n=84)
- 25 mcg intranasal BID, 12 weeks
- FIQ score reduction
- −18.3 points vs −6.1 placebo
- VPAC2-mediated glial inhibition
- Statistically significant but requires larger cohort validation
- Chronic pain rodent model
- 100 mcg/kg SC daily, 4 weeks
- Mechanical pain threshold
- 60% improvement vs baseline
- Substance P suppression + GABAergic enhancement
- Translates to human equivalence of 8 mg/day; delivery route limits direct comparison
- Inflammatory arthritis model
- VIP gene therapy (AAV vector)
- Joint inflammation score
- 45% reduction at 8 weeks
- M1→M2 macrophage polarization
- Gene therapy route impractical for fibromyalgia; demonstrates mechanistic proof
- Fibromyalgia + insomnia cohort
- 50 mcg intranasal before bed, 8 weeks
- Sleep quality index
- +2.4 points vs +0.6 placebo
- Suprachiasmatic nucleus VIP receptor activation
- Sleep improvement secondary to pain reduction or direct circadian effect unclear